The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2 overexpressing adenocarcinoma of the esophagus or gastroesophageal junction. The TRAP-2 study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513797-22-00

Enrollment

408

Registered

2024-11-01

Start date

2022-03-09

Completion date

Unknown

Last updated

2025-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 positive esophageal adenocarcinoma

Brief summary

overall survival

Detailed description

 Quality-adjusted life years  Progression free survival  Pathological response according to the Mandard criteria  R0 resection rate  Safety in terms of: o Toxicity defined according to CTCAE v5.0 criteria. o Post-operative complications according to the Clavien - Dindo classification.  Percentage completion of chemotherapy and radiation treatment.  Quality of life

Interventions

DRUGHerceptin 150 mg powder for concentrate for solution for infusion

DRUGPerjeta 420 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
 Quality-adjusted life years  Progression free survival  Pathological response according to the Mandard criteria  R0 resection rate  Safety in terms of: o Toxicity defined according to CTCAE v5.0 criteria. o Post-operative complications according to the Clavien - Dindo classification.  Percentage completion of chemotherapy and radiation treatment.  Quality of life	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026